Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2025-12-26 @ 4:05 AM
Study NCT ID:
NCT01630018
Status:
COMPLETED
Last Update Posted:
2016-09-22
First Post:
2012-03-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial
Sponsor:
Chong Kun Dang Pharmaceutical
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-01
Start Date Type:
None
Primary Completion Date:
2014-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-06
Completion Date Type:
ACTUAL
First Submit Date:
2012-03-06
First Submit QC Date:
None
Study First Post Date:
2012-06-28
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-09-20
Last Update Post Date:
2016-09-22
Last Update Post Date Type:
ESTIMATED